Flash Finance

Windlas Biotech LimitedWINDLASCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹917.40
MCap ₹1,893 Cr · P/E 28.5
Windlas Biotech Limited — Stock analysis & AI research Windlas Biotech Limited — Multibagger AI analysis Windlas Biotech Limited — Seasonality — best & worst months Windlas Biotech Limited — Technical indicators & charts Windlas Biotech Limited — Technical setup — score, trend, support & resistance Windlas Biotech Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Promoters Increasing Stake 📈 RSI Oversold Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹248 Cr
Sales · Jun 2026
+18.1% YoY
₹27 Cr
Operating Profit · Jun 2026
+0.6% YoY
10.8%
OPM % · Jun 2026
-14.3% YoY
₹18 Cr
Net Profit · Jun 2026
-0.1% YoY
₹8.46
EPS · Jun 2026
+0.4% YoY

📝 Windlas Biotech Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Windlas Biotech Limited reported revenue of ₹248 crore for the quarter ended June 2026 (Q1 FY27), up 18.1% from ₹210 crore in the same quarter last year, and up 4.2% sequentially over the March 2026 quarter.

Net profit fell 0.1% year-on-year to ₹18 crore, from ₹18 crore. Earnings per share (EPS) came in at ₹8.46.

Operating profit stood at ₹27 crore — an operating margin (OPM) of 10.8%, compared with 12.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Windlas Biotech Limited posted revenue of ₹904 crore, a growth of 18.9% over FY25, with a net profit of ₹66 crore (up 9.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹942 crore with a net profit of ₹66 crore.

Valuation snapshot

At the current price of ₹917.40, WINDLAS has a market capitalisation of ₹1,893 crore and a trailing P/E of about 28.5.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 6th-largest of the 20 companies we track by market value.

Shareholding pattern

As of May 2026, promoters held 63.31%, foreign institutional investors (FIIs) 0.99%, domestic institutional investors (DIIs) 10.20%, public shareholders 25.49% of Windlas Biotech Limited.

Promoter holding rose from 61.90% to 63.31% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,893 Cr
Current Price ?
₹917.4
P/E ?
28.49above ind
Industry P/E ?
21.30
P/B ?
3.26
P/S ?
2.01
P/FCF ?
51.17
Enterprise Value ?
₹1,928 Cr
EV/EBITDA ?
18.43
PEG ?
1.68
Earnings Yield ?
3.8%
Dividend Yield ?
0.63%
Profitability & Returns
Sales (TTM) ?
₹942 Cr
OPM ?
11.1%
Profit after tax (TTM) ?
₹66 Cr
EPS (TTM) ?
₹32.20
ROCE ?
16.0%
ROE ?
11.4%
ROA ?
7.3%
Growth
Sales — latest qtr ?
₹248 Cr
PAT — latest qtr ?
₹18 Cr
YoY qtr sales growth ?
18.1%
YoY qtr profit growth ?
-0.1%
Sales growth (3y) ?
21%
Sales growth (5y) ?
16%
Profit growth (3y) ?
17%
Profit growth (5y) ?
16%
Financial Health
Debt ?
₹35 Cr
Debt to Equity ?
0.06
Interest Coverage ?
16.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
63.31%
Change in promoter holding ?
1.33%
Pledged percentage ?
N/A
Market
Return 3 months ?
8.7%
Return 6 months ?
5.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 120141145153162171175187195203210222233238248 +18.1% +4.2%
Operating Profit 141617192022212325262729242527 +0.6% +6.7%
Other Income 223334454554545 -2.4% +27.8%
Interest 000000011111112 +56.0% +65.0%
Depreciation 343334677878887 -3.2% -9.9%
Profit Before Tax 131516182023182020212324202023 -1.4% +14.7%
Net Profit 91112141517131616161818151618 -0.1% +10.3%
EPS 4.235.375.796.757.268.176.477.497.457.778.438.487.127.588.46 +0.4% +11.6%
OPM % 11.7% 11.7% 11.8% 12.2% 12.5% 12.8% 11.9% 12.3% 12.6% 12.6% 12.6% 12.8% 10.5% 10.5% 10.8% -14.3% +2.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹760 Cr ₹904 Cr ₹942 Cr +18.9%
Operating Profit ₹94 Cr ₹104 Cr ₹105 Cr +11.0%
OPM % 12.38% 11.56% 11.11% -6.6%
NPM % 8.03% 7.36% 7.06% -8.3%
Other Income ₹18 Cr ₹17 Cr ₹17 Cr -3.1%
Depreciation ₹28 Cr ₹31 Cr ₹31 Cr +9.9%
Interest ₹4 Cr ₹4 Cr ₹5 Cr -0.7%
EBIT ₹66 Cr ₹74 Cr ₹74 Cr +11.5%
PBT ₹80 Cr ₹87 Cr ₹86 Cr +8.8%
Tax ₹19 Cr ₹16 Cr ₹16 Cr -12.9%
Net Profit ₹61 Cr ₹66 Cr ₹66 Cr +9.0%
EPS ₹29.18 ₹31.61 ₹31.64 +8.3%
Material Cost ₹493 Cr ₹405 Cr ₹448 Cr -18.0%
Employee Cost ₹123 Cr ₹111 Cr ₹123 Cr -9.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10101011 +10.0%
Reserves 392440495570 +15.2%
Borrowings 543335 +6.1%
Other Liabilities 122173222291 +31.1%
Total Liabilities 529626760907 +19.3%
Fixed Assets 109179223217 -2.7%
CWIP 156556 +1020.0%
Investments 107173223268 +20.2%
Other Assets 298268308366 +18.8%
Total Assets 529626760907 +19.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 6110968105 +54.4%
Cash from Investing Activity -14-92-74-92 -24.3%
Cash from Financing Activity -44-151-13 -1400.0%
Net Cash Flow 32-50 +100.0%
Free Cash Flow -9711637 +131.2%
CFO/OP 117%163%95%115% +21.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 83798092 +15.0%
Inventory Days 84576340 -36.5%
Days Payable 98121129156 +20.9%
Cash Conversion Cycle 691514-24 -271.4%
Working Capital Days 713217123 +623.5%
ROCE % 14%18%17%16% -5.9%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026May 2026 % Chg
Promoters 61.98%61.98%61.90%63.31% +2.3%
FIIs 1.11%0.93%0.60%0.99% +65.0%
DIIs 11.44%11.44%11.80%10.20% -13.6%
Public 25.48%25.64%25.69%25.49% -0.8%
No. of Shareholders 45,43345,46144,76946,084 +2.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Windlas Biotech Limited's revenue in Q1 FY27?
Windlas Biotech Limited reported revenue of ₹248 crore for the quarter ended June 2026 (Q1 FY27), up 18.1% from ₹210 crore in the same quarter last year, and up 4.2% sequentially over the March 2026 quarter.
What was Windlas Biotech Limited's net profit in Q1 FY27?
Net profit fell 0.1% year-on-year to ₹18 crore, from ₹18 crore. Earnings per share (EPS) came in at ₹8.46.
What is WINDLAS's market capitalisation and P/E ratio?
At the current price of ₹917.40, WINDLAS has a market capitalisation of ₹1,893 crore and a trailing P/E of about 28.5.
Who owns Windlas Biotech Limited? (shareholding pattern)
As of May 2026, promoters held 63.31%, foreign institutional investors (FIIs) 0.99%, domestic institutional investors (DIIs) 10.20%, public shareholders 25.49% of Windlas Biotech Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI